Podcasts about Glenmark

Víš, že kdybychom rozprostřeli všechny naše cévy, mohli bychom dvakrát obkroužit Zemi? A taky, že onemocnění cév patří mezi nejčastější zdravotní problémy – postihuje přibližně každého třetího dospělého? Co všechno může naše cévy ohrozit? O tom jsme si povídali s MUDr. Helenou Čermákovou, internistkou a angioložkou na Klinice transplantační chirurgie v IKEM. Epizodu si můžeš pustit také na Youtube. Co se v epizodě dozvíš?

Audio roundup of selected biopharma industry content from Scrip over the business week ended 23 August 2024. In this episode: CMS's price reveal better than expected?; new diabetes risk data for Zepbound; can J&J's lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark's shifting revenues. https://scrip.citeline.com/SC150795/Quick-Listen-Scrips-Five-MustKnow-Things Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

On today's podcast, Dom talks with North Canterbury farmer Ian Knowles about dealing with drought, fire chairing the Hurunui District Landcare Group... He talks with Simon Lee from Glenaray Station in Northern Southland about the concept of 'lean farming', managing staff and its recent Beef+ Lamb NZ field day... He talks with Heidi Hitchman, founder of Summit Solutions, about what the service offers for farmers, her large rural workforce and the 'work from home' model... And he talks with Farm Focus CEO Auriga Martin about its analysis of its latest round up of data showing how Kiwi farms are performing. Tune in daily for the latest and greatest REX rural content on your favourite streaming platform, visit rexonline.co.nz and follow us on Instagram, Facebook and LinkedIn for more.See omnystudio.com/listener for privacy information.

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — Verona wins FDA nod for COPD  The bad — FDA issues CRL to Merck-Daiichi lung cancer ADC  The ugly — Glenmark recalls 114 batches of potassium chloride capsules 

Darshan discussed crucial updates to the Department of Justice's (DOJ) corporate enforcement policies, particularly impacting FDA-regulated industries like pharmaceuticals and medical devices. The DOJ's focus on mergers and acquisitions (M&A) emphasizes the importance of compliance professionals throughout the entire process.Key Highlights:1. Corporate Enforcement Policies Update: The DOJ has introduced significant changes to its corporate enforcement policies, impacting companies engaged in M&A transactions. Compliance professionals are now essential stakeholders at the due diligence table.2. Antitrust Division's Impact on Pharma: Recent cases involving pharmaceutical companies Teva and Glenmark showcased the DOJ's shift in approach. Divestiture of a core product was required, marking the first instance of such a demand in a corporate criminal resolution.3. Compliance Program and Compensation: The new pilot program mandates companies to incorporate compliance-promoting criteria into their compensation systems. The DOJ urges companies to address this now, emphasizing the need for proactive compliance policies.4. Voluntary Self-Disclosure Policy: The DOJ announced a voluntary self-disclosure policy, creating a safe harbor for companies that promptly report wrongdoing. The policy encourages self-reporting, offering a presumption of declination for qualifying companies.5. Qualification for Safe Harbor: Companies must disclose misconduct within six months of acquisition, with one year to fully remediate. These deadlines may be extended based on case specifics. The Safe Harbor applies only to criminal conduct in bona fide M&A transactions.6. DOJ Principles: The DOJ aims to hold wrongdoers accountable, incentivize compliance, and deter repeat offenses. The new policy offers a presumption of declination for companies self-disclosing, cooperating, and remediating.7. Impact on Pharma and Device Companies: FDA-regulated industries, particularly pharmaceutical and device manufacturers, may benefit from the clear safe harbor. Voluntary self-disclosure, under the new policy, could become more common in the life sciences sector.8. Considerations and Conclusion: Companies must carefully evaluate when self-disclosure is appropriate, with minor regulatory violations potentially better handled directly with the FDA. Compliance teams play a vital role, and ongoing developments at the intersection of compliance and FDA regulation will be closely monitored.

Professors Wytske Fokkens and Joaquim Mullol discuss the burden of smell loss and the emerging science on how inflammation drives olfactory dysfunction in patients with CRSwNP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Professor Wytske Fokkens, MD, PhD has received consultation/speaker fees from Novartis, Sanofi, GSK and Dianosic.  Professor Joaquim Mullol, MD, PhD reports have received research grants, participated in clinical trials, been a member of Speaking Bureaus and Advisory Boards from Allakos, AstraZeneca, Glenmark, GSK, Menarini, MSD, Mitsubishi-Tanabe, Noucour/Uriach Group, Novartis, Optinose, Proctor & Gamble, Sanofi-Genzyme, Regeneron Pharmaceuticals, Viatris. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400013 v1.0 01/2024 MAT-US-24000221 v1.0 - P Expiration Date: 01/08/2026

This week we are hosting Mr Sourabh Sengupta, the Vice President of global supply chain planning at Glenmark Pharmaceuticals. With over 25+ years of Supply Chain experience across companies like Glenmark, Cipla, General Motors and more, listen in on some of his insightful thoughts on topics ranging from Indian consumer behavior to consequences of the Gaza War on the global supply chain. He's also got some valuable advice for a successful career in operations.

In this episode, find out about tax authorities imposing penalty of Rs 1.8 cr on Hindustan Zinc, also find out about Glenmark announcing interim dividend of Rs 22.50 share Business Term of the Day: Guarantee

In this episode of Market Minutes, Sucheta Anchaliya talks about all the important factors to watch today developments Glenmark Pharma stake sale, Vedanta's fund raise, SVJN to global market setup. Also catch George Thomas of Quantum AMC in Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, keys data points and developing trends

In this episode of Market Minutes, Sucheta Anchaliya talks about all the important factors to watch today, from Nykaa, Glenmark Pharma, Patanjali and JK cement Q1 results to global market setup. Also, catch Arun Kumar Mantri Founder of Mantri Finmart in Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, keys data points and developing trends

Ian Knowles has had a different start into farming than most. ..  He trained and worked in ag science and, well he's never shaken off that interest in research…  His farm in Waipara, North Canterbury, is one big petri dish…  And for his endeavours, he's been awarded the Ballance Farm Environment Award for Canterbury…  He joins us now.See omnystudio.com/listener for privacy information.

The SGX Nifty is suggesting a solid start to begin trade with and that's because the US markets ended with gains of 1 to 2 percent. The Down Jones was up 2.1 percent, the S&P 500 was rallying 1.5 percent, and NASDAQ gaining 1.1 percent. The Nasdaq notched its sixth straight week of gains for the first time since 2020. The reason for the optimism and the rally in the global markets was one. The non-farm payroll data was stronger than what the street was anticipating, which means the labour data continues to be resilient yet. The street doesn't think that the fed will continue with its rate hiking cycle. The US Fed will be meeting on June 13 and 14, and the expectations are that it will pause at the upcoming meeting. The reason for the same is because the hourly wages that ticked lower than what the street anticipating and also the unemployment rate also went up. There was a big outperforming seed in the broader markets last week. So while the lift was volatile, it ended with a gain of just about 10.2 percent oscillating between 18400 to 18700. In terms of flows on Friday, the domestic investors bought Rs 581 crore, while the foreign investors sold Rs 658 crore. The big event to track this week will be the RBI monetary policy on June 8.  . In terms of individual stocks, Mankind, Glenmark, SBI Life, among other stocks should be on your radar. Tune to Marketbuzz Podcast for more news and cues ahead of today's session

Equity Cash: KPIT Tech, Lupin Equity Derivatives: Asian Paints Fut, ICICI Bank 900 CE, Glenmark 450 CE Index Derivatives: Nifty 18200 CE, Nifty Bank 42600 CE --- Send in a voice message: https://anchor.fm/kunvarji-group1/message

Equity Cash: Syrma SGS, GAIL Stocks Derivatives: VEDL FUT, Glenmark 420 CALL Index Derivative: Nifty 18000 CALL, Nifty Bank 41500 CALL --- Send in a voice message: https://anchor.fm/kunvarji-group1/message

Anders Glenmark skivdebuterade som 19-åring i början på 70-talet och har sedan dess varit en av våra mest älskade sångare med låtar som Hon har blommor i sitt hår, Mare mare, Hon sa och kanske inte minst tillsammans med killarna i GES När vi gräver guld i USA. Han har även producerat andra artister som Eva Dahlgren, Patrik Isaksson och Magnus Uggla för att nämna några. Hur ser hans liv ut nu? Varför är det roligare att turnera när man är 60+? Vad hände när han tog time out och hur har hans liv förändrats efter den sällsynta diagnosen kavernom. Detta och mycket mer kommer här, men först - leta namn och låttitel.

Frequent bounce-backs and corrections are keeping investors confused about the market trajectory. As Covid-19 cases continue to spike across the globe and vaccine efficacy unknown against the new variant, adopting a prudent investment strategy is the way forward to safeguard one's portfolio. An analysis by ICICI Direct shows that all major market corrections since April 2020 got arrested within 9-11% range. And buying in each of these corrections has been fruitful for investors as indices subsequently retested previous highs. Given this, research analysts at ICICI Direct expect markets to maintain the same rhythm this time around too. In the current scenario, after a 31 per cent rally in the past six months, the benchmarks have corrected 9 per cent from their respective lifetime highs. Therefore, the ongoing correction should be capitalised on as an incremental buying opportunity to ride the structural uptrend But, will putting your money behind the classic defensive bets prove to be beneficial this time? Let's find out. Over the past few months, healthcare stocks have witnessed retracement while IT stocks have been consolidating in a narrow range. As these stocks form fresh base at higher levels, analysts foresee decent returns from the space in days ahead. Select pharma stocks, for instance, can rally up to 15 per cent on the bourses as discussion around expediting vaccination drive and booster shots to the vulnerable population gains currency. As per tech charts, shares of Alembic Pharma and Cipla are eyeing 15% and 13% upside, respectively, as both these counters are trading firmly above their support zones. Those of Glenmark and Torrent Pharma, meanwhile, may gain between 11% and 15%. That said, the overall industry's outlook is not very optimistic as growth is likely to slow and export growth could fall to low single-digits. Moreover, there are cost and supply challenges due to energy crisis in China. The other defensive sector – FMCG – can also be on investor radar, though, it is expected to continue with its underperformance. So far in financial year 2021-22, with the S&P BSE FMCG index has risen 6.3 per cent as compared to over 15 per cent gain in the benchmark S&P BSE Sensex during this period. The underperformance was mostly on account of concerns of a slowdown in the overall consumption as a result of rising input costs in an inflationary environment. And data backs this too. The latest survey by NielsenIQ shows that India's FMCG market grew 12.6 per cent in the September 2021 quarter compared to the same period last year. However, rural markets witnessed a slowdown due to a dip in consumption with value growth coming in at 9.4 per cent. Volumes, in the rural market, contracted 2.9 per cent due to lower consumption of items like cooking oil and packaged grocery. However, as an investment strategy, analysts are bullish on companies like ITC, Nestle, HUL Colgate and Britannia. Moreover easing input cost pressures, amid drop in crude oil prices, will aid the performance of companies, says AK Prabhakar, head of research at IDBI Capital. He says, the fall in the market from its recent high has further corrected the valuation in a number of these counters. Thus, a blanket investment in defensive plays should be avoided. Analysts suggest focus should be on companies with strong balance sheets and with those having a favourable risk-reward set-up. On Thursday, weekly F&O expiry, monthly auto sales data and global cues will dictate the secondary market trend. The primary market, meanwhile, will be dominated by three public offers. Tega Industries' initial share sale will enter its second day today while Star Health and Allied Insurance's IPO will close later in the day. Additionally, Anand Rathi Wealth, will launch its initial public offering today. The price band for the offer has been fixed at Rs 530-550 per share and the company aims to mobilise Rs 660 crore. Watch Video

Anton gästas av Martin "Färska Prinzen" Svensson och de pratar om ABBA och en massa annat. Stötta Antons kulturella gärning på http://www.patreon.com/antonmagnussonpodcast

Neste episódio eu recebi o Carlos Grzelak que há mais de 20 anos se dedica a indústria da saúde com passagens pela Lilly, Pfizer, Chiesi, Glenmark, Emcure e agora Mundipharma, uma empresa com sede em Londres e que no Brasil atua com Oftalmologia, Oncologia e Dor.Falamos sobre o atual momento da empresa e as expectativas dele para o Brasil e o futuro da Indústria da Saúde.#viaoral

Anna Stadling bjuder in Anders Glenmark för att prata om hur GES bildades, historien bakom världshiten One night in Bangkok och om en sanslös nyårsnatt vid millenieskiftet då deras vägar korsades. Det blir även samtal om sammetslena röster, Annas kärlek till Texas och hur man på förhand vet om en låt kommer bli en hit. Jukeboxen med Anna Stadling sänds i P4 med start 19.03.

On this episode of The Shape of Work podcast, our guest is Clint Misquitta.Besides leading learning and talent at Edelweiss Tokio Life Insurance, Clint is an author, traveller, and L&D leader. He has vast experience ranging from working in pharmaceutical behemoth Glenmark to Edelweiss, an insurance company.With a background that extensive, it's no surprise this episode covers a lot of ground. We discuss:The story behind his book, Ruthless DictatorsLearning styles you should know before creating an L&D strategyWhy developing your employees professionally is the key to retentionTalent acquisition and recruitment trends in 2021Ruthless dictators: inspiration and the central idea behind this book:Clint tells us about the story behind writing his book. According to him, this book was an accident, not a choice. He tells us about the woman from Magna publications that he came across while working on a project. That is when they discussed his love for writing. Clint further talks about the title of the book. He finalized “Ruthless Dictators” because of his love for history. He has a keen interest in learning about these dictators and their situation.Segregating the framework of Learning and Development:Clint starts on a very simple yet insightful note- the difference between being taught and learning.Is tech a major factor in the success of L&D programs:“Learning is the process, and the tech is the tool to aid the process.”According to Clint, tech will not help if the process is not correct. People who have to prioritize other tasks over learning have to understand where the issue lies. The answer is simple- there is no clarity and alignment in the process.The edge is to try and create a strong strategy to manage this process-Clarity- The learner should know why the learning is necessary and how it relates to his aspirations.Alignment- They should ensure that their manager is on board with his learning process. Most managers encourage this and facilitate the employee to upskill him.It is the entire process of learning above which the tech providers stand. The organizations have to work with the managers to create a mature framework. Without this framework, tech tools cannot help. Moreover, it is necessary to understand that learning is a social endeavor. The process is more important than the tools used. Tech organizations need to understand this strategy and provide solutions to different companies accordingly. They need to collaborate with them effectively. Clint feels that the company should pay for maturing their learning process, not the content or platform.BONUS: Willing to figure out ways to save your employee turnover cost? Read our latest blog post.Follow Clint on LinkedInProduced by: Priya BhattPodcast host: Lokesh Gautam

Glenmark Life Sciences is a API and CDMO subsidiary of Glenmark Pharmaceutical, which is leading research based pharmaceutical company of India.

2021 fyller Anders Glenmarks hitalbum "99" 30 år! Det ska vi fira genom att gå igenom låt för låt på plattan och låta Anders berätta om sina alster och vi får höra hemligheterna bakom text och musik. Vad sjunger han egentligen i sticket på "Mare, Mare", vem var Anna som dansade, har han åkt en Greyhound Bus, varför heter skivan "99" och vilken låt är en låt om sex..? Vi lär oss också om soundet "vemodig" och om att han slängt alla demos och tidigt material på tippen. Och hur tycker han plattan står sig idag? Gäst: Johanna Lundberg. See acast.com/privacy for privacy and opt-out information.

Season 2 of De Zero Stories Podcasts commences with a critical topic - Thyroid - Lack of Awareness and how a Health Tech Company aims to solve this impending issue of lack of awareness among Indian women.  In Conversation with Hiren Dhuvad, CEO Of Indigital Technologies, this podcast episode throws lights on InDigital's patented product called Wifi Clinics, which empowers the doctors to take awareness to the patient's phone as they enter the hospital or clinic. The beauty is that they don't need internet connectivity to harness this information. Imagine a remote village in India, which is still lurking behind on health awareness. Kanopi connects with them in their native language and gives authentic information about the Thyroid and many other lifestyle ailments. Profile of Hiren Dhuvad: Twitter: https://mobile.twitter.com/hiren_rx LinkedIn: https://www.linkedin.com/in/hirendhuvad Profile of InDigital Technologies: Founded in 2015 by Mr Hiren Dhuvad, Indigital Technologies LLP is a pioneer Health-Tech firm. The company envisions to digitize the pharmaceutical healthcare marketing space by delivering award-winning technology solutions that are disruptive. The healthcare industry has been least disrupted by technology for so long in terms of doctor & patient engagement and education strategies. Indigital Technologies LLP, a research based digital healthcare technology company with 3 provisional patents on its name, had recently been associated with Thyronorm for its campaign named ‘WiFi Thyroid Clinics'. Indigital came up with a solution to convert a doctor's clinic into WiFi Thyroid Clinic where a patient was educated through internet-less solution, on Thyroid disorder and its management. The company converted 252 endocrinologist's clinics of Thyronorm into WiFi Thyroid Clinics with the help of Kanopi, a patented product of Indigital. Indigital Technologies have rich expertise in working with more than 50 top global healthcare companies like Abbott, Cipla, Pfizer, BI, Sanofi, Glenmark, Lupin, Sun Pharma etc. It has worked with over 2,50,000 doctors and empowered more than 7.5 million patients worldwide. The boot-strapped and self-sustained company has witnessed a higher double-digit growth CAGR. It has embraced a ground-breaking customer-first approach with a global presence in 3 countries- India, USA, and UAE. Furthermore, the company would like to expand its operations in Indian regions like Mumbai, Delhi, Gurgaon, Hyderabad, Bangaluru, and Ahmedabad. In future, the company wishes to geographically expand across the UK and EU with a widened product portfolio in the patient education segment.

A waiver of intellectual property rights on Covid-19 vaccines and drugs alone may not benefit developing countries including India in the battle against the deadly disease. Murali Neelakantan, Former Global General Counsel of Cipla and Glenmark, and Vikas Dandekar, Editor, Pharma and Healthcare, ET Prime, explain what's at stake for the patent holders and developing nations. The clip featuring Bill Gates used in the podcast belongs to Sky News.

In the last few weeks, every Monday has brought some unexpected moves at the opening, and in the week gone by, too, it surprised everyone with a decent gap-down opening. A lot of domestic factors weighed heavily on the market to trigger the downside gap and global cues had very little to contribute in it. Fortunately, the Nifty managed to hold the key support in the initial hiccup and in fact, a good amount of buying at lower levels led to a complete recovery in the latter half. Barring Tuesday’s sluggishness, we witnessed a slow and steady up move throughout the remaining part of the week to reclaim the 14,800-mark. On a weekly basis, the Nifty managed to clock over a percent gains in the inaugurated week of May month. Since the last few days, the index seems to have lost its charm. Although it has been maintaining its positive posture throughout, the overall movement is quite lethargic. All the key indices like Nifty, Bank Nifty, and Nifty IT are trapped in a slender range. As far as higher levels are concerned for Nifty, 14,900 – 14,960 – 15,050 are the levels to watch out for, whereas on the flip side, 14,750 – 14,600 – 14,450 are to be considered as immediate supports. Till the time we do not see the index coming out of its congestion zone, such boredom is likely to continue. Thus, it is better not to trade aggressively in the index, and carrying of overnight positions is strictly avoided. Taking a glance at the intraday charts, we can see the range shrinking drastically, and hence, there is a high possibility that we may see a decisive breakout soon. Although key indices are displaying complete boredom, the broader market is clearly not short of actions. In fact, there were numerous themes that played out exceedingly well throughout the week. Every now and then we are observing some sector chipping in to keep the traders’ fraternity engrossed all the time. Hence, the pragmatic approach would be to keep focusing on such potential movers to obtain better trading opportunities. One of the notable observations is the development in the ‘Nifty Midcap’ index. In the latter half of the week, it has managed to surpass the higher boundary of the cluster of resistance by a small margin. A couple of follow-up moves in this basket would provide the real impetus for the next leg of the rally. Here is a list of stocks for the next 3-4 weeks:Overall, this stock has been quiet for a long time and in fact, we did not see its participation in the humongous rally that was seen in some of the financial counters lately. However, the short-term trend has been strongly up for this counter. After a brief pause, we witnessed a decisive breakout from the ‘Bullish Flag’ pattern on May 7. The volumes were decent and the momentum oscillators were also positively poised. Considering all this, we recommend going long for a target of Rs.440 in the coming days. The strict stop loss can be placed at Rs.412.The pharma space once again started buzzing in the week gone by due to the havoc created by second wave of COVID-19. The move was mainly led by Lupin and then others joined the party. Glenmark was consolidating in a range since last few days. However, with Friday’s up move, the stock price confirmed a ‘Bullish Flag’ pattern on the daily chart. The price move is accompanied by sizable volumes, indicating a strong buying interest in the counter. Traders are advised to go long for a target of Rs.645 in the coming days. The strict stop loss can be placed at Rs 564. Disclaimer: The views and investment tips expressed by the investment experts on Moneycontrol.com are his own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

The Nifty50 on the daily time frame is trading within a downward tilt channel pattern. On 29th April prices witnessed a stiff resistance at the upper band of the channel pattern and slip almost 600 points post facing the resistance. On Wednesday 05th May, Indian equity benchmarks made an optimistic start, led by buying in Pharma, and telecom stocks. In the second half of the trading session, Nifty continued to trade in fine contour on continued buying by funds and retail investors as RBI Governor unveiled liquidity support measures amid rising COVID-19 cases in India. Indian bourses on the daily chart are trading above their 100-day exponential moving average which is placed above the lower band of the channel pattern acting as a crucial support zone for the index. The index has broken out its Rising channel pattern on the weekly chart. After trading within the rising channel pattern for more than 12 months, the index registered a decisive breakdown that suggests if prices continued to trade below their trend line resistance then there will a change in the trend from upward to negative. Currently, Nifty Pharma Index is outperforming the Benchmark index and the Pharma index has broken out its Pole flag pattern on the weekly chart. After consolidating for more than 10 weeks in a flag pattern, the pharma index registered a decisive breakout that suggests a change in the trend from sideways to upward. The Nifty50 index is holding the key support zone, but the chart pattern suggests that there might be some action expected in the index if the price remains above the support zone or breaks the crucial resistance zone which rests at 14,900 levels in the coming trading sessions. Support for the index is placed near 14,245 levels which are clubbed with a 100-DEMA. Here is a list of stock recommendations for the next 3-4 weeks:  The prices were trading in a falling channel pattern for the past two months and it also followed lower bottom lower high formation on the daily chart. SBI has given a decisive break out of a falling channel pattern and currently hovering above the upper band of the falling channel pattern on the daily interval. The stock is trading above its 100-day exponential moving averages on the daily time frame, which is positive for the prices in the near term. When we observe volume activity there has been above-average volume set up for the past few days. Momentum oscillator RSI (14) has given a horizontal trend line breakout which was placed at 42 levels. Currently, RSI is reading near 50 levels with a bullish crossover, which indicates bullish momentum will likely to continue in the near term.The stock has broken out of its smaller degree symmetrical pattern at 3821.85 levels on 12 April 2021 after consolidating for more than three months in a symmetrical pattern. The price registered a decisive break out of the said pattern that suggests a change in the trend from sideways to upward. Besides, the price is trading above its 21-period EMA, which is acting as a crucial support zone below the upper band of the triangle pattern. The momentum oscillator RSI (14-period) is trading above 60 levels, indicating a positive trend for the stock. MACD is also showing a positive crossover and sustaining above the centerline, further indicates an upside direction for the stock. The Parabolic SAR indicator is below the current market prices and acting as short-term support for the stock at the lower band of the pattern. Divi’s Laboratories price seems to be in a positive phase based on the above technical outlook and approaching the key resistance zone. The chart pattern suggests that there might be more action expected in Divi’s Laboratories if the price breaks the important resistance levels in the coming weeks.Glenmark has moved up after consolidation on the weekly time frame suggesting a rise in optimism among the investors. The stock has also witnessed a breakout of a symmetrical pattern on the daily scale. Prices have witnessed a spectacular rally in the last four weeks leading to an almost 30 percent gain. The recent leg of strong up-move is also supported by strong volumes and it also resembles a strong consolidation breakout. Prices are trading above its exponential moving averages (50 & 100) on the weekly chart. Momentum Oscillator RSI (14) is reading above 60 levels with positive crossover, which is positive for the counter. The MACD indicator is reading above its line of polarity with positive sentiments.

Selling pressure at higher levels once again dampened market sentiment as Nifty ended below 14,300 on April 20. Although pharma and auto counters tried to give some support but selling pressure in financials, IT and FMCG counters dragged the market down. On the derivatives front, Call writers were seen adding hefty open interest at 14,500, 14,600 and 14,700 strikes which should act as a major hurdle for Nifty and will cap any sharp upside. On the technical front, 14,200-14,150 will act as major support for Nifty. However, we could witness a fresh round of selling in the index if the 14,150 level is broken decisively in the upcoming sessions. Here are three buy calls for the next 2-3 weeks: Info Edge (India) | LTP: Rs 4,772 | Target price: Rs 5,625 | Stop loss: Rs 4,280 | Upside: 18% After testing a 52-week high of Rs 5,880 in January 2021, this stock slipped back sharply towards Rs 4,100 due to profit-booking at higher levels. However, it took support at its 200-day exponential moving average on the daily interval and made a V-shaped recovery to once again reclaim Rs 4,700 level. At the current juncture, the stock can be seen trading well above its short and long-term moving averages with the formation of higher highs. Additionally, the stock has formed an inverted head and shoulder pattern on the daily charts and is on the verge of a fresh breakout above the neckline of the pattern formation. The positive divergences on secondary oscillators along with price action suggest the next upswing in the prices. Traders can accumulate the stock in the range of Rs 4,760-4,780 for the upside target of Rs 5,625. Glenmark Pharmaceuticals | LTP: Rs 569 | Target price: Rs 652 | Stop loss: Rs 505 | Upside: 15% Last week, this stock gave a fresh breakout after a prolonged consolidation of nearly eight months. Prices had been seen a fluctuation in a broader range of Rs 445-545 since August 2020, sustaining well above their 200-day exponential moving average on the daily interval. Now, prices are keeping well above their 200-day exponential moving average on the weekly charts as well which points towards the strength in the stock from a medium-term perspective. On the technical front, follow-through buying has been observed in the stock after a breakout above the falling trendline of a sloping channel on short-term charts. Traders can accumulate the stock in the range of Rs 560-570 for the upside target of Rs 652. Lupin | LTP: Rs 1,088.70 | Target price: Rs 1,172 | Stop loss: Rs 1,020 | Upside: 8% This stock has been consistently moving in a broader range of Rs 980-1,100 for the last three months. At the current juncture, the stock has formed a bullish flag pattern on the weekly interval and given a breakout above the same. Positive divergences on secondary oscillators suggest that the stock is all set for a next upswing at the prices as additional volumes with a rise in prices suggest long build-up in the stock. Traders can accumulate the stock in the range of Rs 1,075-1,090 for the upside target of Rs 1,172. (The author is Senior Technical Analyst at SMC Global Securities) Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

This podcast gives a 360 degree overview of the Indian Stock markets and the index of Nifty 50. The Nifty 50 looks in a bullish trend after that new high was made yesterday. Though todays move is bearish , it has rested on earlier swing high which was at 11320.The stock pick for today is Glenmark Pharma. The interesting cup handle formation is seen which promises higher returns.Support the show (https://www.youtube.com/channel/UCpo00Gr2UYgA-EQzrQRGaiQ?view_as=subscriber)

After witnessing over 1 per cent rally in both the Sensex and Nifty last week, investors will continue to focus on June quarter earnings. Further, stock-specific developments, global cues and updates related to Covid-19 will also remain on their radar. That apart, listing of Rossari Biotech on July 23 will be closely watched by the market participants. The public offer of the company, which was open for subscription between July 13 and July 15, was subscribed 79.4 times. On the earnings front, over 250 companies, including Bajaj Finance, Axis Bank, Hindustan Unilver (HUL), ITC, L&T, and Asian Paints, among others are slated to report their quarterly numbers this week. Today, as many as 40 companies are scheduled to report their results today. The list includes names such as ACC, Den Networks, and SBI Cards. Meanwhile, India on Sunday reported its highest single day spike of 38,902 cases and 543 deaths. The caseload rose to 1,113,400, according to Worldometer. However, the the Union Health Ministry said that India's Covid-19 fatality rate is "progressively falling" and is currently at 2.49 per cent, which is one of the lowest in the world.  And, now let's focus on some of the key developments that took place during the weekend. Private sector lender HDFC Bank posted a 5.15 per cent rise in profit before tax (PBT) at Rs 8,973.8 crore for the first quarter ended June 2020 (Q1FY21). It had posted a PBT of Rs 8,533.6 crore in quarter ended June 2019 (Q1FY20). The Net Interest Income (NII) grew by 17.8 per cent on a Year-on-Year basis.  Pharma company Glenmark, which markets favipiravir under brand Fabiflu for treatment of mild-to-moderate Covid-19 patients, has come under the scanner of ‘the country’s drug regulator overpricing of the drug and claims of its therapeutic efficacy. India’s largest airline IndiGo is in talks to raise around Rs 3,000 crore while travel demand has collapsed during the pandemic, according to a Business Standard report. And, now, let's have a quick look at the market snapshot for today. The Indian markets are likely to see a flat-to-negative start today as indicated by the SGX Nifty which was trading around 10,875.80 levels, down 42 points around 7:28 AM. On the global front, Asian shares were subdued in the early trade as investors eyed efforts to stitch together more fiscal stimulus in the eurozone and United States to help economies ride out the effects of a record jump in Covid-19 cases globally.

I Hitfabrikens sommarserie bjuder jag in barn till kända musiker som fritt får välja ut sina favoritlåtar från sin förälders låtskatt. Hör vilka låtar Ann-Louise Hansons dotter Josefin Glenmark valt. Josefin är uppväxt i föräldrarnas studio som hon hade som lekstuga. Hör också om deras relation idag och hur det är att jobba med sin mamma. Hur blev en sminkväska en bra barnvakt bakom scenen när mamma uppträdde? Josefin låter oss höra låtar som beskriver hennes släkt, om bortglömda samarbeten med Grammy-belönade artister och om avsaknaden av skandaler...fast lite får du höra om schismen som splittrade Glenmark-familjen. See acast.com/privacy for privacy and opt-out information.

Chairing an all-party meeting on the violent clash in Galwan in which 20 Indian soldiers lost their lives, Prime Minister Narendra Modi on Friday said, “Neither has anybody intruded into our territory, nor is anybody inside our territory, nor any of our posts have been captured,” drawing strong reactions on social media. Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. The BCCI on Friday said it will review IPL's sponsorship deals, including the one with Chinese mobile manufacturing company Vivo, in a meeting next week after 20 Indian soldiers were killed during a clash with Chinese troops in eastern Ladakh. Download the Deccan Herald app for Android devices here: https://bit.ly/2UgttIO Download the Deccan Herald app for iOS devices here: https://apple.co/30eOFD6 For latest news and updates, log on to www.deccanherald.com Check out our e-paper www.deccanheraldepaper.com To read news on the go, sign up to our Telegram channel t.me/deccanheraldnews

Anders Glenmark bjuder in Leif Käck som skrivit många av Anders texter samt kallas "GES fjärde medlem". Det blir en salig blandning, från slamrig punk till spröda toner från the Carpenters. Hör om minnen från deras långa och innehållsrika karriärer, om Anders passion för stråkarrangemang, varför losertexter är de bästa texterna...och vilken var låten som spelades om och om igen i bilstereon under den där turbulenta Europasemestern...? Programmet sändes första gången 2018.

·         Markets make a strong comeback, Sensex surges 353 points while Nifty reclaims 11,000-mark to end at 11,029, up 104             points on across-the-board buying; ·         Nifty Pharma index hits 5-year low; Glenmark at 7-year low post Q1 results; ·         HDFC Life Insurance slumped 7% post block deal, but recovered later Benchmark indices ended nearly a per cent higher on Wednesday amid across-the-board buying and positive global cues. Investor sentiment got a major boost as the US President Donald Trump's decision to delay imposition of additional tariff on Chinese imports doused trade-war concerns. Further, benign inflation back home, opened room for more rate cuts by the Reserve Bank of India (RBI). The benchmark S&P BSE Sensex settled at 37,311 levels, up 353 points or 0.96 per cent, lifted by Reliance Industries, Infosys, ICICI Bank, and HDFC. Vedanta, Tata Steel, YES Bank, and Tech Mahindra were the top gainers on the index, while Sun Pharma, ONGC, Tata Motors, and Asian Paints emerged as the top laggards. The broader Nifty50 added 104 points, or 0.95 per cent, to end at 11,029. On the sectoral front, all the sectors, except pharmaceuticals, ended the day with gains. Nifty Pharma index shed 4 per cent in the intra-day trade to hit a 5-year low on BSE. The index ended 1.4 per cent lower. On the contrary, Nifty metal was the top gainer, up over 2 per cent, followed by Nifty public sector bank index, up over 1 per cent. In the broader market, S&P BSE mid-cap settled at 13,487 level, up 124 points or 0.93 per cent. The S&P BSE small-cap, on the other hand, closed at 12,580 levels, up 61 points or 0.48 per cent. Among individual stocks, shares of HDFC Life Insurance Company slumped as much as 7.5 per cent to Rs 490 apiece on the BSE in the early trade on Wednesday after reports said co-promoter Standard Life sold more than 3 per cent stake in the company via block deal. The stock, however, pared losses to end at Rs 515.20, down just 0.75 per cent. On the other hand, Dixon Technologies surged 19 per cent in the intra-day trade on the back of strong June quarter results before settling at Rs 2,347, up over 18 per cent. That's all we have for you in today's post-market podcast. For the latest news on business, markets, and more, please log on to Business-Standard.com

Indian shares are likely to open higher on Wednesday supported by a rally in global stock markets and after retail inflation data boosted chances of a rate cut. Asian shares advanced after the US delayed tariffs on some Chinese imports. Indian’s CPI inflation eased marginally to 3.15 percent in July, but remained below the RBI’s target of 4 percent, strengthening chances of a rate cut. Indian benchmark indices ended lower on Tuesday, dragged by banking and automotive stocks, as investors remained cautious in the absence of an announcement about a government fiscal stimulus package to curb slowdown and rollback of FPI surcharge, ahead of key inflation data. The Sensex ended 624 points down at 36,958 while the broader Nifty50 index lost 184 points to end the day at 10,926. At 7.50 AM, the SGX Nifty futures traded 19.50 points, or 0.18 percent, higher at 10,940, indicating a positive start for the Sensex and the Nifty. Stocks to watch: Future Retail, Glenmark Pharma, Coal India, Infosys in focus.

Indian benchmark indices are likely to open little changed on Monday following muted trades in global markets and a spike in oil prices. Asian shares traded cautiously as investors await US-China trade negotiations ahead of G20 meeting this weekend. Oil prices rose on worries over heightened tensions between the US and Iran. Indian benchmark indices on Friday ended over 1 percent lower on weak global cues. The Sensex ended 407 points lower at 39,194, while the broader Nifty50 index lost 108 points to end at 11,724.  At 7.00 AM, SGX Nifty an early indicator of the Nifty 50's trend in India, traded at 1.50 points, or 0.01 percent, higher at 11,755.50, indicating a flat start to the Sensex and the Nifty 50. Stocks to watch: IndusInd Bank, BHEL, Glenmark Pharma in focus.

Vi träffar gitarristen och låtskrivaren Lasse Andersson som berättar varför fläktorgeln va den bästa läraren, om geniet Glenmark och varför man ska bli bättre entreprenör. Mycket Nöje! 

Ravi Dharamshi is CIO of Valuequest Investment Advisors and manages investments of around Rs 500 crore. In his role, Dharamshi is sector agnostic but has a long history with pharma. He began investing in pharma and healthcare stocks back in 2002 and worked previously with Rare Enterprises. Some of his key bets in pharma have included Lupin, Glenmark, Natco and Divi's. Tune into Dharamshi's journey of investing in pharma and healthcare stocks, how the landscape has changed and his take on top industry trends and stocks. Happy listening!

Aditya Khemka, fund Manager at DSP Investment Managers, breaks down the pharma sector from a portfolio perspective. Khemka, who was previously with Glenmark and tracked the pharma and health sectors at Lehman Brothers and Nomura, provides crucial insights into the big risks, challenges and opportunities of investing in pharma stocks. Happy listening!

En Actualidad Empresarial, el único podcast sobre empresas en Colombia, escuche además la información sobre los planes de expansión que tienen otras compañías como la farmacéutica Glenmark, Cavelier Abogados, entre otras. Conéctese todos los domingos y escúchenos en Dinero.com

En Actualidad Empresarial, el único podcast sobre empresas en Colombia, escuche además la información sobre los planes de expansión que tienen otras compañías como la farmacéutica Glenmark, Cavelier Abogados, entre otras. Conéctese todos los domingos y escúchenos en Dinero.com

En Actualidad Empresarial, el único podcast sobre empresas en Colombia, escuche además la información sobre los planes de expansión que tienen otras compañías como la farmacéutica Glenmark, Cavelier Abogados, entre otras. Conéctese todos los domingos y escúchenos en Dinero.com

Detta är avsnitt 180 och spelades in den 26 augusti, och eftersom 180 skrivs CLXXX med romerska siffror låter det som en bilmodell som Mercedes kunde ha släppt och därför handlar veckans avsnitt om: FEEDBACK OCH BACKLOG:* IKEA Trådfri väggvårta kommer i oktober* HASS.io knapp för att starta och stänga av servrar* Prisjakt för att filtrera* MacBook Pro, "dongle hell" och dockningsstation, eller varför inte en skärm?* Lyft erbjuder gratis skjuts till vallokaler den 6:e november* Därför byter vi mellan Android och iOS MICROSOFT:* Teams är klart, enligt Microsoft   * Men hur gör man om man behöver logga in med flera olika konton? APPLE:* Apple kastar ut gambling-appar från App Store i Kina GOOGLE:* Google har blivit stämda för location-data i en Class Action Lawsuit* Datally   * En app för att hantera din surfpott* Files Go   * För att rensa upp lite i ditt filsystem i Android* Dualboot:a Chrome och Windows på en ChromeBook* Google Frankrike stänger sitt egna konto i Google+ ÖVRIGA NYHETER:* Amerikanska senatorer vill stoppa 3D-skrivare ALLMÄNT TIPS:* Windows 95 som app för samtliga OS* Simon Stålenhag gör coola och snygga tavlor   * BONUSLÄNK: https://www.demilked.com/pop-culture-digital-art-filip-hodas/ LYSSNARFRÅGA:* Tempo-app för att rangordna låtar   * “Simple BPM Detector” på Android   * Sök efter “BPM finder” eller “BPM detector” på iOS DISKUSSION:* Molnbackup av data, bland annat bilder   * David kör BackBlaze.com   * Johan kör Windows-NAS hemma och kör sedan Duplicati PRYLLISTA:* David: Apple TV 4k* Johan: Skruvdragare   * BONUSLÄNK: Regnigt kafé DELTAGARE I AVSNITTET:* David: @dlilja * Johan: @JoPe72 FRÅNVARANDE DELTAGARE I AVSNITTET:* Björn: @DiverseTips* Mats: @Mahu78 EGNA LÄNKAR:* En Liten Podd Om IT på webben* En Liten Podd Om IT på Facebook LÄNKAR TILL VART MAN HITTAR PODDEN FÖR ATT LYSSNA:* Apple Podcaster (iTunes)* Overcast * Acast* Spotify* Sticher

Med sig har han Leif Käck som skrivit många av Anders texter samt kallas "GES fjärde medlem". Tillsammans väljer de musiken i veckans program. Det blir en salig blandning från slamrig Punk med Ramones till spröda toner från Carpenters. Om Anders passion för stråkarrangemang, varför losertexter är de bästa texterna...och vilken var låten som spelades om och om igen i bilstereon under den där turbulenta Europasemestern...? Jukeboxen på lördag, kl 19.03 i P4.

Måns kan bli konkurrent till sig själv i sällskap av utmanarna med Anders Glenmark och Maia Hirasawa. Spänningen är också stor om Laleh hörs i dubbel dos på listan och är hon fortfarande i topp? Förutom veckans tre utmanare avslöjar Carolina Norén resultatet där det rör sig om hårfina marginaler i toppen. Anders Glenmark – Anders låg redan som 19-åring på Svensktoppen, året var 1972. Nu är han aktuell med en ny EP från vilken vi testar ”Som En Sol”, en låt som han skrivit som en hyllning till sin fru.Måns Zelmerlöw – Måns gör ett försök att placera ytterligare en låt på listan det här året. Nya singeln som är utmanare heter "Hanging On To Nothing".Maia Hirasawa – Maia har tidigare släppt musik på både engelska och svenska. Nu är det svenska som gäller på nya albumet ”Vacker Och Ful”. Första singeln heter ”Rusar” och är aktuell som utmanare.

Benny rår inte på Laleh och Miriam Ellen Sundberg 21-åriga Ellen Sundberg skriver sin egen musik och besök i Nashville och turné med Doug Seegers har countryinfluerat hennes musik som dock även låter pop. Hon släppte sitt debutalbum för ganska precis tre år sen. Nu är hon aktuell med nya singeln Favorite Town. Lasse Stefanz Dansbandsveteraner med mångåriga svensktoppsplaceringar. Efetr snart 50 år i branschen fortsätter de att släppa nytt material som till exempel Hanna kommer hem.Anders Glenmark Anders debuterade på Svensktoppen 1972. Vi har hört honom i Melodifestivalen, som en tredjedel av G.E.S och som producent åt andra. Nu väljer han efter tio år utanför rampljuset att göra comeback med bland annat låten Vackrare. PS Missa inte finalen av Svensktoppen Nästa nästa söndag. Vi direktsänder med start klockan 14. /Carolina NorénSvensktoppsjuryn består av 500 personer som valts ut av CMA Research. Juryns sammansättning motsvarar Sveriges befolkning 16-79 år. Resultatet presenteras av på söndagar 11.03-12.00 i Sveriges Radio P4. Programmet går att lyssna på i efterhand i 30 dagar på sverigesradio.se och i appen Sveriges Radio Play. Svensktoppen finns på Facebook. Här hittar du sidan

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

En 1871, en una excavación de huesos de moa en la ciénaga de Glenmark, en la región de Canterbury, en la isla Sur de Nueva Zelanda, aparecieron los restos de un águila enorme, desconocida para la ciencia. El águila de Haast es la mayor que conocemos, con un peso de quince kilos y una envergadura de hasta tres metros.